Streetbeat News

SDZNY

Sandoz Group AG

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

40.94

Mkt cap

18B

Volume

High

41.70

P/E Ratio

-2073.00

52-wk high

46.80

Low

40.94

Div yield

0.01

52-wk low

27.79

The article compares Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS) to determine which offers better value for investors in the Medical - Drugs sector.

Portfolio Pulse from

December 20, 2024 | 6:00 pm

Sandoz Group AG Sponsored ADR (SDZNY) has been upgraded to a Zacks Rank #1 (Strong Buy) due to growing optimism about its earnings prospects.

Portfolio Pulse from

December 16, 2024 | 6:15 pm

Sandoz Group AG Sponsored ADR (SDZNY) is showing a hammer chart pattern, suggesting it has found support after recent losses. Combined with upward earnings estimate revisions, this indicates a potential trend reversal.

Portfolio Pulse from

December 16, 2024 | 4:15 pm

The article compares Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS) as potential value investments in the Medical - Drugs sector, focusing on which might be the better undervalued stock option.

Portfolio Pulse from

December 04, 2024 | 6:00 pm

The article compares Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS) to determine which stock offers better value for investors interested in the Medical - Drugs sector.

Portfolio Pulse from

November 18, 2024 | 6:00 pm

Agomab Therapeutics NV has appointed Colin Bond, former CFO of Sandoz, to its Board of Directors as a non-executive Director and Chairman of the Audit Committee. Colin Bond brings over three decades of finance experience, including fifteen years as a CFO at listed biopharmaceutical companies.

Portfolio Pulse from

November 18, 2024 | 10:15 am

Sandoz has received European Commission approval for Afqlir® (aflibercept), a biosimilar to Eylea®, to treat retinal diseases. This strengthens Sandoz's biosimilar portfolio and reinforces its leadership in the global and European markets.

Portfolio Pulse from

November 15, 2024 | 6:15 am

Sandoz has raised its 2024 net sales growth guidance to high-single digits in constant currency, driven by strong biosimilars and generics demand. The company maintains its core EBITDA margin guidance at approximately 20%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:07 am

Sandoz reported a strong third quarter with net sales of $2.6 billion, marking a 12% increase in constant currencies. The growth was driven by a 37% rise in biosimilars and accelerated generics growth in Europe.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:06 am

Sandoz has expanded its U.S. oncology portfolio with the FDA approval of a generic version of Paclitaxel, targeting metastatic breast cancer. This is the first FDA-approved ANDA for this medicine, and it is expected to drive near-term growth in the U.S. market.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 5:45 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.